source
- Alumis' TYK2 lupus drug fails mid-stage trial, CEO says clear path forwardAlumis announced that its TYK2 inhibitor did not meet primary endpoints in a mid-stage study in patients with lupus. The trial, which was the company's lead program, was designed to evaluate effic…
- Trump unveils pricing agreements with midsize biotech firms; Novartis halts CAR-T trial after patient deathsThe White House announced that President Trump has struck new pricing agreements with a group of midsize biotechnology companies, aiming to adjust drug costs. Novartis disclosed that it is pausing…